EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Enhanced CYP2C19-mediated drug-drug interaction risk with escitalopram in geriatric populations

Seonyoung Byoun, Dong-Gyu Heo, Minsoo Lee, Ryunghwa Lee, Yuanyuan Li, Ju-Yeun Lee, Eunjin Hong, Wooin Lee

Frontiers in Pharmacology · 05.01.2026 · 16

DOI: 10.3389/fphar.2025.1711196 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 05.01.2026. Verfasst von Seonyoung Byoun und 7 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, Republic of Korea. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Seoul National University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Escitalopram (S-CIT) is commonly prescribed for depression and anxiety in older patients. Previous research has reported that the effect of CYP2C19 polymorphism on S-CIT pharmacokinetics is more pronounced in older adults than in young adults. The current study investigated whether older adults taking S-CIT face a greater risk for CYP2C19-mediated drug-drug interaction (DDI) than young adults.

Methods

Using a physiologically-based pharmacokinetic (PBPK) model, we quantitatively compared the risk of CYP2C19-mediated DDIs in older adults taking S-CIT with any of four CYP2C19 inhibitors (omeprazole, esomeprazole, fluconazole, and fluoxetine). These CYP2C19 inhibitors were selected based on their prevalence of co-administration with S-CIT, as determined by a retrospective analysis of the 2019 Korean National Health Insurance Service senior cohort database. Results and Discussion Our PBPK modeling-based simulations predicted that the extent of DDI incurred by S-CIT would be greater in older adults than in young adults and vary significantly by CYP2C19 phenotypes (extensive, intermediate, and poor metabolizers). Based on the prediction results, we propose CYP2C19 phenotype-guided S-CIT dosing strategies for older adults. Implementing the proposed dosing recommendation may reduce the incidence of potentially inappropriate use of medication and adverse events in older adults prescribed S-CIT.

Schlagwörter

Stichwörter der Autor:innen

CYP2C19PBPK modelingdrug-drug interactionsescitalopramgeriatric population

Autor:innen und Institutionen

  • College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, Republic of Korea.
  • College of Pharmacy, Dongguk University-Seoul, Goyang-si, Republic of Korea.

Förderung

  • Seoul National University

Zitieren

APA

Byoun, S., Heo, D. G., Lee, M., Lee, R., Li, Y., Lee, J. Y., Hong, E., & Lee, W. (2026). Enhanced CYP2C19-mediated drug-drug interaction risk with escitalopram in geriatric populations. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1711196

Vancouver

Byoun S, Heo DG, Lee M, Lee R, Li Y, Lee JY, et al. Enhanced CYP2C19-mediated drug-drug interaction risk with escitalopram in geriatric populations. Frontiers in Pharmacology. 2026;16. doi:10.3389/fphar.2025.1711196

BibTeX
@article{Byoun2026,
  author = {Byoun, Seonyoung and Heo, Dong-Gyu and Lee, Minsoo and Lee, Ryunghwa and Li, Yuanyuan and Lee, Ju-Yeun and Hong, Eunjin and Lee, Wooin},
  title = {Enhanced CYP2C19-mediated drug-drug interaction risk with escitalopram in geriatric populations},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fphar.2025.1711196}
}
Kostenlos starten →